Related Experiment Video
Updated: Aug 1, 2025

08:41
Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2
Published on: November 5, 2021
2.8K
[Recent Advances in SARS-CoV-2-Induced Immune Thrombocytopenia --Review]
Xin-Hui Zhou1, Chang-Geng Ruan1, Yang He2
1Department of Thrombosis and Hemostasis, The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, Suzhou 215006, Jiangsu Province, China.
Zhongguo Shi Yan Xue Ye Xue Za Zhi
|April 25, 2023
Summary
SARS-CoV-2-induced immune thrombocytopenia (ITP) is an autoimmune condition following COVID-19. Treatment requires careful consideration due to bleeding and thrombosis risks, with specific therapies reserved for severe cases.
Area of Science:
- Immunology
- Hematology
- Infectious Diseases
Background:
- SARS-CoV-2-induced immune thrombocytopenia (ITP) is an autoimmune disorder linked to viral infections.
- Diagnosis often involves excluding other causes of thrombocytopenia in COVID-19 patients.
Conclusions:
- Individualized treatment is crucial for SARS-CoV-2-induced ITP patients.
- TPO-RAs should be used cautiously in refractory cases due to potential thrombotic side effects.

